Book contents
- Treatment of Dystonia
- Treatment of Dystonia
- Copyright page
- Contents
- Contributors
- Preface
- 1 Development of the Concept of Dystonia as a Disease, a Syndrome and a Movement Phenomenology
- Section I Basics
- Section II Botulinum Toxin Therapy
- 21 The Global Market for Botulinum Toxin
- 22 Molecular Mechanisms of Botulinum Toxin
- 23 Indirect Central Nervous System Effects of Botulinum Toxin
- 24 Direct Central Nervous System Effects of Botulinum Neurotoxin
- 25 Analgesic Effects of Botulinum Toxins
- 26 Manufacture of Commercial Botulinum Neurotoxins for Human Treatment
- 27 Pharmacology of Botulinum Toxins
- 28 Immunology of Botulinum Toxin Therapy
- 29 Use of Non-A/Non-B Botulinum Toxins
- 30 Clinical Muscular Anatomy for the Botulinum Toxin Injector
- 31 Ultrasound Guidance for Botulinum Toxin Application
- 32 Treatment Algorithms and Injection Schemes for Botulinum Toxin Therapy of Dystonia
- 33 Botulinum Toxin Therapy for Cervical Dystonia
- 34 Botulinum Toxin Therapy for Cranial Dystonia
- 35 Botulinum Toxin Therapy for Spasmodic Dysphonia
- 36 Botulinum Toxin Therapy for Writer’s Cramp and Other Focal Hand Dystonias
- 37 Botulinum Toxin Therapy for Bruxism
- 38 Treatment of Blepharospasm With Eyelid-Opening Apraxia
- 39 Organisation of a Botulinum Toxin Clinic
- Section III Musician’s Dystonia
- Section IV Psychogenic Dystonia
- Section V Treatment of Paediatric Dystonia
- Section VI Rehabilitation of Dystonia
- Section VII Pharmacotherapy for Dystonia
- Section VIII Surgical Treatment of Dystonia
- Section IX Deep Brain Stimulation for Dystonia
- Section X Emerging Therapies for Dystonia
- Section XI Future Trends in Dystonia Therapy
- Book part
- Index
- References
21 - The Global Market for Botulinum Toxin
from Section II - Botulinum Toxin Therapy
Published online by Cambridge University Press: 31 May 2018
By
Book contents
- Treatment of Dystonia
- Treatment of Dystonia
- Copyright page
- Contents
- Contributors
- Preface
- 1 Development of the Concept of Dystonia as a Disease, a Syndrome and a Movement Phenomenology
- Section I Basics
- Section II Botulinum Toxin Therapy
- 21 The Global Market for Botulinum Toxin
- 22 Molecular Mechanisms of Botulinum Toxin
- 23 Indirect Central Nervous System Effects of Botulinum Toxin
- 24 Direct Central Nervous System Effects of Botulinum Neurotoxin
- 25 Analgesic Effects of Botulinum Toxins
- 26 Manufacture of Commercial Botulinum Neurotoxins for Human Treatment
- 27 Pharmacology of Botulinum Toxins
- 28 Immunology of Botulinum Toxin Therapy
- 29 Use of Non-A/Non-B Botulinum Toxins
- 30 Clinical Muscular Anatomy for the Botulinum Toxin Injector
- 31 Ultrasound Guidance for Botulinum Toxin Application
- 32 Treatment Algorithms and Injection Schemes for Botulinum Toxin Therapy of Dystonia
- 33 Botulinum Toxin Therapy for Cervical Dystonia
- 34 Botulinum Toxin Therapy for Cranial Dystonia
- 35 Botulinum Toxin Therapy for Spasmodic Dysphonia
- 36 Botulinum Toxin Therapy for Writer’s Cramp and Other Focal Hand Dystonias
- 37 Botulinum Toxin Therapy for Bruxism
- 38 Treatment of Blepharospasm With Eyelid-Opening Apraxia
- 39 Organisation of a Botulinum Toxin Clinic
- Section III Musician’s Dystonia
- Section IV Psychogenic Dystonia
- Section V Treatment of Paediatric Dystonia
- Section VI Rehabilitation of Dystonia
- Section VII Pharmacotherapy for Dystonia
- Section VIII Surgical Treatment of Dystonia
- Section IX Deep Brain Stimulation for Dystonia
- Section X Emerging Therapies for Dystonia
- Section XI Future Trends in Dystonia Therapy
- Book part
- Index
- References
Summary
A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
- Type
- Chapter
- Information
- Treatment of Dystonia , pp. 99 - 101Publisher: Cambridge University PressPrint publication year: 2018
References
Careta, MF, Delgado, L and Patriota, R, 2015. Report of allergic reaction after application of botulinum toxin. Aesthet Surg J. 35: NP102–NP105.CrossRefGoogle ScholarPubMed
Eisele, KH, Fink, K, Vey, M and Taylor, HV, 2011. Studies on the dissociation of botulinum neurotoxin type A complexes. Toxicon. 57: 555–565.CrossRefGoogle ScholarPubMed
Elston, JS and Russell, RW, 1985. Effect of treatment with botulinum toxin on neurogenic blepharospasm. Br Med J (Clin Res Ed). 290: 1857–1859.CrossRefGoogle ScholarPubMed
Fujinaga, Y, Sugawara, Y and Matsumura, T, 2013. Uptake of botulinum neurotoxin in the intestine. Curr Top Microbiol Immunol. 364: 45–59.Google ScholarPubMed
Glogau, R, Blitzer, A, Brandt, F, Kane, M, Monheit, GD and Waugh, JM, 2012. Results of a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of a botulinum toxin type A topical gel for the treatment of moderate-to-severe lateral canthal lines. J Drugs Dermatol. 11: 38–45.Google Scholar
Kamin, W, Staubach, P, Klar-Hlawatsch, B and Knuf, M, 2006. Anaphylaxis after vaccination due to hypersensitivity to gelatin. Klin Padiatr. 218: 92–94.CrossRefGoogle ScholarPubMed
Kim, BJ, Kwon, HH, Park, SY, et al., 2014. Double-blind, randomized non-inferiority trial of a novel botulinum toxin A processed from the strain CBFC26, compared with onabotulinumtoxin A in the treatment of glabellar lines. J Eur Acad Dermatol Venereol. 28: 1761–1767.Google Scholar
Masuyer, G, Chaddock, JA, Foster, KA and Acharya, KR, 2014. Engineered botulinum neurotoxins as new therapeutics. Annu Rev Pharmacol Toxicol. 54: 27–51.CrossRefGoogle ScholarPubMed
Pickett, A, 2013. Historical aspects of botulinum toxin used clinically: part I – is that the right serotype? The Botulinum J. 2: 176.Google Scholar
Pickett, A, 2015. Historical aspects of botulinum toxin used clinically: part II: overcoming resistance. The Botulinum J. doi: https://doi.org/10.1504/TBJ.2015.078134.CrossRefGoogle Scholar
Scott, AB, Rosenbaum, A and Collins, CC, 1973. Pharmacologic weakening of extraocular muscles. Invest Ophthalmol. 12: 924–927.Google ScholarPubMed